To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.9862100.
Rikke Tetzschner and Ajenthen G. Ranjan are co-first authors.
Intensive insulin treatment for type 1 diabetes is associated with high risk of mild hypoglycemia. Mild hypoglycemia is usually treated orally with glucose, which may contribute to weight gain. Subcutaneous injection of low-dose glucagon may be a new treatment option for some occasions of mild hypoglycemia in individuals aiming for optimal glycemic control without gaining weight. We investigated under which occasions patients were interested to use low-dose glucagon.
In a prospective 2-week event-driven survey, participants registered every event of mild hypoglycemia (sensor or blood glucose ≤ 3.9 mmol/l and/or hypoglycemia symptoms). For each hypoglycemia event, participants registered whether they would have preferred to use low-dose glucagon if the treatment had been available.
A total of 51 participants (13 men, mean ± SD age 43.6 ± 12.5 years, HbA1c 7.3 ± 0.7% (57 ± 8 mmol/mol), BMI 24.9 ± 3 kg/m2) were included. Each participant had on average 10 (range 3–23) mild hypoglycemia events during the 2-week survey period. Glucagon was preferred in 58% of the 514 mild hypoglycemia events (p > 0.05). Twelve percent of the participants had no desire to use glucagon for any hypoglycemia event. The preference pattern did not differ between sex, patient treatment modalities, and possible causes for hypoglycemia (all p > 0.05).
This study showed that a majority of our participants with type 1 diabetes were interested in using low-dose glucagon for the treatment of mild hypoglycemia.
This work was funded by a research grant from the Copenhagen University Hospital Hvidovre and by the Danish Diabetes Academy supported by the Novo Nordisk Foundation.
DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:177–88. CrossRef
DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995;18:1415–27. CrossRef
Gubitosi-Klug RA, Braffett BH, White NH, et al. Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the DCCT/EDIC study. Diabetes Care. 2017;40:1010–6. CrossRef
Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97:4383–9. CrossRef
Fulcher G, Singer J, Castañeda R, et al. The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. J Med Econ. 2014;17:751–61. CrossRef
Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27:398–404. CrossRef
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;2:CD009122.
Delahanty LM, Halford BN. The role of diet behaviors in achieving glycemic control intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care. 1993;16:1453–8. CrossRef
Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the US: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38:971–8. CrossRef
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72. CrossRef
Minges KE, Whittemore R, Weinzimer SA, Irwin ML, Redeker NS, Grey M. Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D Exchange Clinic Registry. Diabet Res Clin Pract. 2017;126:68–78. CrossRef
Ranjan A, Schmidt S, Madsbad S, Holst JJ, Nørgaard K. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. Diabet Obes Metab. 2016;18:410–8. CrossRef
Chakravarthy M, Parsons S, Lassman ME, et al. Effects of 13-hour hyperglucagonemia on energy expenditure and hepatic glucose production in humans. Diabetes. 2017;66:36–44. CrossRef
Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol. 1992;262:975–80. CrossRef
Rickels MR, DuBose SN, Toschi E, et al. Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care. 2018;41:1909–16. CrossRef
Ranjan A, Schmidt S, Damm-Frydenberg C, et al. Low-carbohydrate diet impairs the effect of glucagon in the treatment of insulin-induced mild hypoglycemia: a randomized crossover study. Diabetes Care. 2017;40:132–5. CrossRef
Steineck IIK, Ranjan A, Schmidt S, Clausen TR, Holst JJ, Nørgaard K. Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study. Diabetologia. 2019;62(4):582–92. CrossRef
Ranjan A, Nørgaard K, Tetzschner R, et al. Effects of preceding ethanol intake on glucose response to low-dose glucagon in individuals with type 1 diabetes: a randomized, placebo-controlled, crossover study. Diabetes Care. 2018;41:797–806. CrossRef
Bakhtiani PA, El Youssef J, Duell AK, et al. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes. J Diabetes Complicat. 2014;1964:2010–5.
Ranjan A, Wendt SL, Schmidt S, et al. Relationship between optimum mini-doses of glucagon and insulin levels when treating mild hypoglycaemia in patients with type 1 diabetes—a simulation study. Basic Clin Pharmacol Toxicol. 2018;122(3):322–30. CrossRef
- Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study
Ajenthen G. Ranjan
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II